BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457-1464. [PMID: 25532501 DOI: 10.1007/s10620-014-3486-7] [Cited by in Crossref: 173] [Cited by in F6Publishing: 155] [Article Influence: 21.6] [Reference Citation Analysis]
Number Citing Articles
1 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 165.6] [Reference Citation Analysis]
2 Brancaccio G, Salpini R, Piermatteo L, Surdo M, Fini V, Colagrossi L, Cantone M, Battisti A, Oda Y, Di Carlo D, Ceccherini-Silberstein F, Perno CF, Gaeta GB, Svicher V. An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms 2021;9:752. [PMID: 33918474 DOI: 10.3390/microorganisms9040752] [Reference Citation Analysis]
3 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
5 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lim Y, Lee YS, Gwak G, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology 2017;66:772-83. [DOI: 10.1002/hep.29187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
8 Sobhonslidsuk A, Numthavaj P, Wanichanuwat J, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B. Biomed Res Int. 2017;2017:4327385. [PMID: 29214169 DOI: 10.1155/2017/4327385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, Chen C, Mao Q, Zhao W, Ren H, Tan D, Niu J, Chen S, Pan C, Tang H, Wang H, Mao Y, Jia J, Ning Q, Xu M, Wu S, Li J, Zhang X, Zhang W, Xiong C, Hou J. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13:260-269. [PMID: 30977033 DOI: 10.1007/s12072-019-09943-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020;52:500-12. [PMID: 32583915 DOI: 10.1111/apt.15901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Li W, Jia L, Zhao X, Wu X, Tang H. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 2018;18:121. [PMID: 30071845 DOI: 10.1186/s12876-018-0847-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
13 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
14 Chan L, Asriel B, Eaton EF, Wyatt CM. Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr Opin Nephrol Hypertens 2018;27:102-12. [PMID: 29278542 DOI: 10.1097/MNH.0000000000000392] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
15 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
16 Kumar R, Pérez-Del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016;36 Suppl 1:72-7. [PMID: 26725901 DOI: 10.1111/liv.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
17 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J;  Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589. [PMID: 32304611 DOI: 10.1111/liv.14482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
18 García-Cortés M, Ortega-Alonso A, Andrade RJ. Safety of treating acute liver injury and failure. Expert Opin Drug Saf 2021;:1-13. [PMID: 34254839 DOI: 10.1080/14740338.2021.1955854] [Reference Citation Analysis]
19 Kader C, Sunbul M, Das YK, Yarim M, Bedir A, Karaca E, Celikbilek M, Ozaras R. Telbivudine attenuates gentamicin-induced kidney injury in rats. Int J Antimicrob Agents 2017;49:595-602. [PMID: 28373116 DOI: 10.1016/j.ijantimicag.2017.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
20 Zimmerman KO, Smith PB, McMahon AW, Temeck J, Avant D, Murphy D, McCune S. Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration. JAMA Pediatr 2019;173:60-7. [PMID: 30452504 DOI: 10.1001/jamapediatrics.2018.3227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
21 Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver Int 2019;39:484-93. [PMID: 30525275 DOI: 10.1111/liv.14017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019;4:296-304. [PMID: 30795958 DOI: 10.1016/s2468-1253(19)30015-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 5.7] [Reference Citation Analysis]
23 Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. Curr Opin HIV AIDS 2016;11:80-6. [PMID: 26575147 DOI: 10.1097/COH.0000000000000224] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
24 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
25 Huang M, Jie Y, Lin G, Shi H, Li X, Li X, Wu Y, Chong Y. Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients. Clin Drug Investig 2016;36:471-8. [PMID: 26992717 DOI: 10.1007/s40261-016-0392-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Anikhindi SA, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Ideal Cure for Hepatitis B Infection: The Target is in Sight. J Clin Exp Hepatol 2018;8:188-94. [PMID: 29892183 DOI: 10.1016/j.jceh.2017.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
27 Zhang L, Zhang FK. Treatment of chronic hepatitis B with tenofovir. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4279-4287 [DOI: 10.11569/wcjd.v24.i31.4279] [Reference Citation Analysis]
28 Duraisamy GS, Bhosale D, Lipenská I, Huvarova I, Růžek D, Windisch MP, Miller AD. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going? Viruses 2020;12:E998. [PMID: 32906840 DOI: 10.3390/v12090998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
30 Liem KS, Wong DK, Fung S, Zahirieh A, Yim C, Zanjir WR, Feld JJ, Hansen BE, Janssen HLA. Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. J Viral Hepat 2021;28:51-60. [PMID: 32896948 DOI: 10.1111/jvh.13401] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis 2019;6:ofy353. [PMID: 30931346 DOI: 10.1093/ofid/ofy353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
32 Roderburg C, Tacke F, Trautwein C. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. Visc Med. 2016;32:121-126. [PMID: 27413730 DOI: 10.1159/000444990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
33 Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, Yazici S, Ucisik AC, Vahaboglu MH. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. Medeni Med J 2021;36:201-8. [PMID: 34915677 DOI: 10.5222/MMJ.2021.52959] [Reference Citation Analysis]
34 Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Review of Anti-infective Therapy 2018;16:153-61. [DOI: 10.1080/14787210.2018.1428561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
35 Yoo EH, Cho HJ. Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients. Clin Chim Acta 2017;471:308-13. [PMID: 28687350 DOI: 10.1016/j.cca.2017.06.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
36 Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee T. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther 2018;47:1673-81. [DOI: 10.1111/apt.14682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
37 Shi H, Han Z, Liu J, Xue J, Zhang S, Zhu Z, Xia J, Huang M. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. Med Sci Monit 2017;23:5230-6. [PMID: 29095799 DOI: 10.12659/msm.903382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
39 Chang BW, Kaung A, Robbins L, Tran TT. Hepatitis B: Working Towards a Cure. Curr Gastroenterol Rep 2015;17:35. [PMID: 26275560 DOI: 10.1007/s11894-015-0460-2] [Reference Citation Analysis]
40 Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in Development for Hepatitis B. Drugs 2017;77:1263-80. [PMID: 28660478 DOI: 10.1007/s40265-017-0769-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
41 Ibragimov EK, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Odintsov AV, Panevkina SV, Moiseev SV. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Ter Arkh 2019;91:40-7. [PMID: 31094170 DOI: 10.26442/ 00403660.2019.02.000073] [Reference Citation Analysis]
42 Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019;71:35-44. [PMID: 30876946 DOI: 10.1016/j.jhep.2019.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
43 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
44 De Ridder F, Sonneveld MJ, Lenz O, Janssen HLA, Talloen W, Hansen BE. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials. J Viral Hepat 2021;28:1563-9. [PMID: 34435408 DOI: 10.1111/jvh.13599] [Reference Citation Analysis]
45 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggar A, Lampertico P. Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2017;. [PMID: 28870666 DOI: 10.1016/j.jhep.2017.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
47 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
48 Park JG, Lee YR, Park SY, Lee HJ, Tak WY, Kweon YO, Jang SY, Chun JM, Han YS, Hur K, Lee HW, Kang MK. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis 2018;50:163-7. [PMID: 29089265 DOI: 10.1016/j.dld.2017.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 43.0] [Reference Citation Analysis]
50 Wooddell CI, Gehring AJ, Yuen MF, Given BD. RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses 2021;13:581. [PMID: 33808298 DOI: 10.3390/v13040581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49:448-456. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
52 Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu RY, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat 2019;26 Suppl 1:32-41. [PMID: 31380582 DOI: 10.1111/jvh.13151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
53 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
54 Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 2017;66:2013-23. [PMID: 27534671 DOI: 10.1136/gutjnl-2015-309300] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
55 Thu AM, Poovorawan K, Kittitrakul C, Nontprasert A, Sriboonvorakul N, Phumratanaprapin W, Tangkijvanich P, Leowattana W, Wilairatana P. Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. BMC Pharmacol Toxicol 2015;16:38. [PMID: 26651337 DOI: 10.1186/s40360-015-0037-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Chotiyaputta W, Poosanasuwansri K, Kiattisunthorn K, Chainuvati S, Tanwandee T. Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction. J Viral Hepat 2021;28:364-72. [PMID: 33047455 DOI: 10.1111/jvh.13420] [Reference Citation Analysis]
57 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
58 Liu Y, Cathcart AL, Delaney WE 4th, Kitrinos KM. Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment. J Virol Methods 2017;249:189-93. [PMID: 28923315 DOI: 10.1016/j.jviromet.2017.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
59 Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol 2017;52:641-51. [PMID: 27699721 DOI: 10.1007/s00535-016-1270-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
60 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
61 Liu YY, Liang XS. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA. World J Hepatol 2018; 10(9): 603-611 [PMID: 30310538 DOI: 10.4254/wjh.v10.i9.603] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
62 Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. J Viral Hepat 2017;24:1089-97. [PMID: 28581644 DOI: 10.1111/jvh.12736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
63 Marcellin P, Estrabaud E. Recent advances in hepatology. Liver Int 2017;37:3-6. [DOI: 10.1111/liv.13323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
64 Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Reference Citation Analysis]
65 Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-montero JV, Benítez L, Esposito I, Barreiro P. Emerging Challenges in Managing Hepatitis B in HIV Patients. Curr HIV/AIDS Rep 2015;12:344-52. [DOI: 10.1007/s11904-015-0275-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
66 Nayagam S, Thursz M. Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. Curr Hepatology Rep 2019;18:300-9. [DOI: 10.1007/s11901-019-00478-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
67 Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol 2020;115:406-14. [PMID: 31895708 DOI: 10.14309/ajg.0000000000000490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24:68-74. [PMID: 27658343 DOI: 10.1111/jvh.12613] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
69 Liu SK, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016;10:697-707. [DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
70 Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, Lee SS, Myers RP, Martin SR, Coffin CS. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepat. 2016;23:15-22. [PMID: 26192022 DOI: 10.1111/jvh.12436] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
71 Nam JY, Chang Y, Cho H, Kang SH, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. J Viral Hepat 2018;25:552-60. [PMID: 29194870 DOI: 10.1111/jvh.12838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
72 Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2019; 17: 1850-1859. e4. [PMID: 30448598 DOI: 10.1016/j.cgh.2018.11.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
73 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
74 Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36 Suppl 1:85-92. [PMID: 26725903 DOI: 10.1111/liv.13003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
75 Alonso S, Guerra AR, Carreira L, Ferrer JÁ, Gutiérrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol 2017;17:168. [PMID: 29268704 DOI: 10.1186/s12876-017-0726-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
76 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Seo HY, Lee HA, Ko SY, Wang JH, Kim JH, Choe WH, Kwon SY. Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B. Clin Mol Hepatol 2017;23:154-9. [PMID: 28479588 DOI: 10.3350/cmh.2016.0067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sobhonslidsuk A, Wanichanuwat J, Numthavaj P, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study. Gastroenterol Res Pract 2016;2016:2952635. [PMID: 27872640 DOI: 10.1155/2016/2952635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
79 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
80 Fung J, Lai C, Seto W, Yuen M. Emerging drugs for the treatment of hepatitis B. Expert Opinion on Emerging Drugs 2016;21:183-93. [DOI: 10.1517/14728214.2016.1162155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
81 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
82 Du Jeong I, Jung SW, Park BR, Lee BU, Park JH, Kim BG, Bang S, Shin JW, Park NH. Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B. Dig Dis Sci 2017;62:2908-14. [DOI: 10.1007/s10620-017-4737-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
83 Boyd A, Dezanet LNC, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses 2021;13:1341. [PMID: 34372547 DOI: 10.3390/v13071341] [Reference Citation Analysis]
84 Viganò M, Invernizzi F, Grossi G, Lampertico P. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. Aliment Pharmacol Ther 2016;44:653-61. [DOI: 10.1111/apt.13751] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
85 Ustianowski A, Arends JE. Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. Infect Dis Ther 2015;4:145-57. [PMID: 26032649 DOI: 10.1007/s40121-015-0070-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
86 Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) vs Viread for the treatment of chronic hepatitis B: First-stage results at week 48. Medicine (Baltimore). 2019;98:e16778. [PMID: 31415381 DOI: 10.1097/md.0000000000016778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat 2021;28:353-63. [PMID: 33051945 DOI: 10.1111/jvh.13418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Audsley J, Avihingsanon A, Littlejohn M, Bowden S, Matthews GV, Fairley CK, Lewin SR, Sasadeusz J. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure? J Acquir Immune Defic Syndr 2020;84:527-33. [PMID: 32692112 DOI: 10.1097/QAI.0000000000002386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Aljumah AA, Bin Selayem NA, Al-Howti SY, Dafallah M, AlGhamdi H, Mokhtar H, Albekairy AM, Sanai FM. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience. J Infect Chemother 2019;25:12-6. [PMID: 30366861 DOI: 10.1016/j.jiac.2018.09.014] [Reference Citation Analysis]
90 Wang LP, Cheng X, Li CY, Dai MJ, Han FZ, Yan XB. Relationship between pre-existing resistance mutations and HBV genotype in patients with HBV related liver cirrhosis. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 891-896 [DOI: 10.11569/wcjd.v25.i10.891] [Reference Citation Analysis]
91 Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology. 2015;62:684-693. [PMID: 25973979 DOI: 10.1002/hep.27894] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
92 Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance. Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. J Viral Hepat 2019;26:278-86. [PMID: 30339311 DOI: 10.1111/jvh.13025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
93 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
94 Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study group. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. J Infect Dis 2020:jiaa192. [PMID: 32318704 DOI: 10.1093/infdis/jiaa192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
96 He L, Ye X, Ma J, Li P, Jiang Y, Hu J, Yang J, Zhou Y, Liang X, Lin Y, Wei H. Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy. BMC Gastroenterol 2019;19:101. [PMID: 31226942 DOI: 10.1186/s12876-019-1020-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
98 Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2018;47:114-22. [PMID: 29023803 DOI: 10.1111/apt.14362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
99 Asghar MS, Ahsan MN, Rasheed U, Hassan M, Jawed R, Abbas MB, Yaseen R, Ali Naqvi SA, Rizvi H, Syed M. Severity of Non-B and Non-C Hepatitis Versus Hepatitis B and C Associated Chronic Liver Disease: A Retrospective, Observational, Comparative Study. Cureus 2020;12:e12294. [PMID: 33520498 DOI: 10.7759/cureus.12294] [Reference Citation Analysis]
100 Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
101 Milazzo L, Gervasoni C, Falvella FS, Cattaneo D, Mazzali C, Ronzi P, Binda F, Cheli S, Sollima S, Antinori S. Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting. Clin Exp Pharmacol Physiol 2017;44:191-6. [PMID: 27809359 DOI: 10.1111/1440-1681.12691] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
102 Dusheiko G, Wang B, Carey I. HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy. Hepatol Int 2016;10:727-9. [DOI: 10.1007/s12072-016-9738-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
103 Liem KS, Gehring AJ, Feld JJ, Janssen HL. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
104 Lee BT, Chang M, Lim C, Bae HS, Fong TL. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. JGH Open 2021;5:258-63. [PMID: 33553665 DOI: 10.1002/jgh3.12481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses 2020;12:E1092. [PMID: 32993173 DOI: 10.3390/v12101092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
106 Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699 [PMID: 34222435 DOI: 10.12998/wjcc.v9.i18.4690] [Reference Citation Analysis]
107 Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39:1868-1875. [PMID: 31136052 DOI: 10.1111/liv.14155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
108 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
109 Laing N, Tufton H, Ochola E, P'Kingston OG, Maini MK, Easom N. Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. Trans R Soc Trop Med Hyg 2019;113:11-7. [PMID: 30452730 DOI: 10.1093/trstmh/try117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
110 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
112 Yim HJ, Kim IH, Suh SJ, Jung YK, Kim JH, Seo YS, Yeon JE, Kim CW, Kwon SY, Park SH, Lee MS, Um SH, Byun KS. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. J Viral Hepat. 2018;25:1321-1330. [PMID: 29772084 DOI: 10.1111/jvh.12934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
113 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
114 Zhou J, Liu YY, Lian JS, Pan LF, Yang JL, Huang JR. Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study. Chin Med J (Engl) 2017;130:914-9. [PMID: 28397720 DOI: 10.4103/0366-6999.204107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
115 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
116 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
117 Lin TF, Hsu PI, Lin KH, Tsay FW, Tsai TJ, Chen YH, Yu HC. Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy. Gastroenterol Res Pract 2017;2017:4192169. [PMID: 28757867 DOI: 10.1155/2017/4192169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
119 Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig 2017;37:233-47. [PMID: 27928739 DOI: 10.1007/s40261-016-0486-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
120 Bernstein DE, Trinh HN, Schiff ER, Smith CI, Mospan AR, Zink RC, Fried MW, Lok AS. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Dig Dis Sci 2021. [PMID: 34059991 DOI: 10.1007/s10620-021-07033-y] [Reference Citation Analysis]
121 Lee D, Yun BC, Seo KI, Han BH, Lee SU, Park ET, Lee JW, Jeong J. Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate. Medicine (Baltimore) 2019;98:e18351. [PMID: 31852136 DOI: 10.1097/MD.0000000000018351] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? Journal of Virus Eradication 2018;4:72-9. [DOI: 10.1016/s2055-6640(20)30248-x] [Cited by in Crossref: 56] [Article Influence: 14.0] [Reference Citation Analysis]
123 Flisiak R, Halota W, Jaroszewicz J, Juszczyk J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M; Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol 2017;3:35-46. [PMID: 28856289 DOI: 10.5114/ceh.2017.67626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
124 Wong GL, Chan HL, Chan HY, Tse CH, Chim AM, Lo AO, Wong VW. Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016;43:145-53. [PMID: 26526395 DOI: 10.1111/apt.13447] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
125 Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 [DOI: 10.5501/wjv.v11.i1.57] [Reference Citation Analysis]
126 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
127 Ahn HJ, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK. Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. PLoS One 2017;12:e0170362. [PMID: 28114428 DOI: 10.1371/journal.pone.0170362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
128 Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
129 Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, Yoo BC, Kwon SY, Gwak GY, Lim YS. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00503-6. [PMID: 33962041 DOI: 10.1016/j.cgh.2021.04.045] [Reference Citation Analysis]
130 Lake-Bakaar GV, Lau D, Kuang PP, Singh K. Controlled Therapy Interruption Improves Host Immune Control of Chronic Hepatitis B Virus Infection in HBeAg-Positive Patients. Viral Immunol 2015;28:564-9. [PMID: 26501982 DOI: 10.1089/vim.2015.0059] [Reference Citation Analysis]
131 Surial B, Béguelin C, Chave JP, Stöckle M, Boillat-Blanco N, Doco-Lecompte T, Bernasconi E, Fehr J, Günthard HF, Schmid P, Walti LN, Furrer H, Rauch A, Wandeler G; and the Swiss HIV Cohort Study. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. J Acquir Immune Defic Syndr 2020;85:227-32. [PMID: 32925387 DOI: 10.1097/QAI.0000000000002429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers (Basel) 2019;11:E1819. [PMID: 31752356 DOI: 10.3390/cancers11111819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
133 Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Xie D, Li Z, Li X. Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med 2019;18:260-8. [PMID: 31258661 DOI: 10.3892/etm.2019.7547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH, Chen CH. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients. J Gastroenterol Hepatol 2016;31:1307-14. [PMID: 26758501 DOI: 10.1111/jgh.13294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
135 Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84-89. [PMID: 29427500 DOI: 10.1111/liv.13641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
136 Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 2017;11:999-1008. [PMID: 28965428 DOI: 10.1080/17474124.2017.1386554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
137 Patricio JA, Lopes PF, Medeiros T, Mendes GF, Silva AA, Esberard EB, Lugon JR, Almeida JR. Tenofovir monotherapy for hepatitis B after 1 year does not produce renal dysfunction, but is associated with hyperparathyroidism not related to vitamin D. Eur J Gastroenterol Hepatol. 2016;28:64-69. [PMID: 26545084 DOI: 10.1097/MEG.0000000000000509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
138 Riveiro-barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-samaniego J, Rivero M, Acero D, Fernandez-bermejo M, Moreno D, Sánchez-pobre P, de Cuenca B, Moreno-palomares JJ, Esteban R, Buti M. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Dig Dis Sci 2017;62:784-93. [DOI: 10.1007/s10620-017-4448-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
139 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 13.4] [Reference Citation Analysis]
140 Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther 2016;43:1311-8. [PMID: 27072504 DOI: 10.1111/apt.13630] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
141 Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
142 Kim D, Lee J, Kim DH, Kang K, Suh SJ, Jung YK, Yim HJ. [A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B]. Korean J Gastroenterol 2016;68:317-20. [PMID: 28025475 DOI: 10.4166/kjg.2016.68.6.317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
143 Brouwer WP. Tenofovir alafenamide for hepatitis B: evolution or revolution? Lancet Gastroenterol Hepatol 2016;1:174-5. [PMID: 28404084 DOI: 10.1016/S2468-1253(16)30083-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Singh US, Mulamoottil VA, Chu CK. 2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants. Med Res Rev 2018;38:977-1002. [DOI: 10.1002/med.21490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
145 Truong J, Shadbolt B, Ooi M, Chitturi S, Kaye G, Farrell GC, Teoh NC. Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world. Intern Med J 2017;47:50-6. [PMID: 27571991 DOI: 10.1111/imj.13244] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Fasano M, Maggi P, Leone A, Volpe A, Fiore JR, Angarano G, Santantonio TA. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Dig Liver Dis 2017;49:530-4. [PMID: 28179096 DOI: 10.1016/j.dld.2017.01.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
147 Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification. Yonsei Med J 2018;59:383-8. [PMID: 29611400 DOI: 10.3349/ymj.2018.59.3.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
148 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
149 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
150 Bourlière M, Rabiega P, Ganne-carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-alias M, Carrat F. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. The Lancet Gastroenterology & Hepatology 2017;2:177-88. [DOI: 10.1016/s2468-1253(16)30189-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 18] [Article Influence: 10.4] [Reference Citation Analysis]
151 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Reference Citation Analysis]
152 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
153 Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44:16-34. [PMID: 27198929 DOI: 10.1111/apt.13659] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
154 Su CW, Wu CY, Lin JT, Ho HJ, Wu JC. Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. J Chin Med Assoc 2020;83:125-33. [PMID: 32015266 DOI: 10.1097/JCMA.0000000000000247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
156 Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802. [DOI: 10.1001/jama.2018.3795] [Cited by in Crossref: 194] [Cited by in F6Publishing: 189] [Article Influence: 48.5] [Reference Citation Analysis]
157 Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol 2020;5:441-53. [PMID: 32087795 DOI: 10.1016/S2468-1253(19)30421-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 15.5] [Reference Citation Analysis]
158 Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017;66:11-18. [PMID: 27545497 DOI: 10.1016/j.jhep.2016.08.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
159 Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, Yu ML. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol 2020;73:62-71. [PMID: 32061869 DOI: 10.1016/j.jhep.2020.01.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]